First results of the growth disorders related twinning programme Partners4Growth implemented at the tertiary university pediatric endocrinology clinics in Bulgaria
Author:
Elkina Stanimira M.1, Halvadzhiyan Irina B.1, Popova Galina Ts.2, Avdjieva-Tzavella Daniela M.3, Stefanova Elisaveta3, Kaleva Nartzis N.4, Stoeva Iva H.3, Petrova Chayka K.1, Iotova Violeta M.5
Affiliation:
1. Department of Pediatrics , Medical University – Pleven , Pleven , Bulgaria 2. Clinic of Pediatrics , Acibadem City Clinic Tokuda Hospital , Sofia , Bulgaria 3. Department of Pediatrics , Medical University – Sofia , Sofia , Bulgaria 4. Department of Pediatrics and Medical Genetics , Medical University – Plovdiv , Plovdiv , Bulgaria 5. Department of Pediatrics , Medical University – Varna , Varna , Bulgaria
Abstract
Abstract
Objectives
Early diagnosis of childhood growth disorders, their timely and proper treatment are important for better outcomes.The aim of the present study was to assess the results of the first 18 months of the growth disorders related twinning programme “Partners4Growth” implemented at all tertiary university pediatric endocrinology clinics in Bulgaria.
Methods
In 2019, Partners4Growth started operation at 7 centres (4 experienced and 3 twin centres) with the main aim of aligning their practices in the shortest possible time. Education of twin centres’ personnel was organized, equipment and methods for growth evaluation and follow-up were standardized. The approach was tested initially at one centre. At baseline and at the 18th month a questionnaire concerning diagnosis and management of recombinant human growth hormone (rhGH) requiring disorders was applied.
Results
A total of 104 new patients were diagnosed compared to 30 in the previous year. Of those, 91 started rhGH treatment – 65 (64 %) GH deficient, 12 (12 %) Turner syndrome, 7 (7 %) Prader–Willi syndrome patients, and 7 (7 %) born small for gestational age without postnatal catch-up, representing 35.8 % of all currently rhGH treated Bulgarian children. A better geographical coverage and more advanced diagnostic and management practices were achieved.
Conclusions
Partners4Growth facilitated the alignment of the tertiary pediatric endocrinology centres competences thus leading to an improved diagnosis and treatment of growth disorders as well as better patients’ access. For its short existence, the Programme increased significantly the number of new patients in the difficult times of COVID-19 pandemic thus justifying its continuation.
Funder
The Program is run by the Bulgarian Pediatric Association with the support of an unrestricted educational grant from the Pfizer company
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference33 articles.
1. Albalawi, N, Alsabah, B, Alrefaei, A, Alatawi, A, Albalawi, M, Al-Enazi, Z, et al.. Short stature in children. Egypt J Hosp Med 2018;70:228–33. https://doi.org/10.12816/0043081. 2. Piwoz, E, Sundberg, S, Rooke, J. Promoting healthy growth: what are the priorities for research and action? Adv Nutr 2012;3:234–41. https://doi.org/10.3945/an.111.001164. 3. Vaivada, T, Akseer, N, Akseer, S, Somaskandan, A, Stefopulos, M, Bhutta, ZA. Stunting in childhood: an overview of global burden, trends, determinants, and drivers of decline. Am J Clin Nutr 2020;112:777–91S. https://doi.org/10.1093/ajcn/nqaa159. 4. Halvadzhiyan, I, Rankova, K, Petrova, C, Galcheva, S, Popova, G, Stefanova, E, et al.. Present practices of growth hormone treatment in childhood. Summary of questionnaire results among tertiary pediatric endocrinology establishments. Sci Endocrinol 2019;4:152–60. 5. Polidori, N, Castorani, V, Mohn, A, Chiarelli, F. Deciphering short stature. Ann Pediatr Endocrinol Metab 2020;25:69–79. https://doi.org/10.6065/apem.2040064.032.
|
|